Additionally, PARP-1 inhibition in vivo can reverse PAH in two models [93] and PARP-1 inhibitor Olaparib is now being explored in clinical trials as a potential PAH therapy following success in cancer trials (ClinicalTrials.gov identifier NCT03251872). The gene discussed is PARP1; the disease is pulmonary arterial hypertension.